#3054
Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study
Introduction:
Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Laing E
Authors:
Laing E,
Kiss N,
Michael M,
Krishnasamy M,
Gough K,
Keywords:
neuroendocrine,
nutrition,
malnutrition,
weight change,
symptoms,
#3050
Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis
Introduction:
Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Clift A
Authors:
Clift A,
Frilling A,
Braat A,
Alsafi A,
Wasan H,
Keywords:
liver,
metastases,
radioembolization,
yttrium,
selective internal radiation therapy,
#3034
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction:
The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Merola E
Authors:
Merola E,
Alonso Gordoa T,
Zhang P,
Al-Toubah T,
Pelle E,
Keywords:
Pancreatic NET,
Somatostatin Analogs,
Grade 2 and 3,
Safety,
Efficacy,